Prognostic value of Ki-67 in patients with ovarian cancer

This study aimed to investigate the prognostic value of Ki-67 antigen (Ki-67) in patients with epithelial ovarian cancer. A retrospective review identified a cohort of 78 patients with epithelial ovarian cancer. The association between Ki-67 expression and clinicopathological characteristics and survival was analyzed. High Ki-67 expression was significantly associated with high stage, high histological grade, ascites, and high level of cancer antigen 125 (CA125) (p = 0.011, p = 0.031, p = 0.033, p = 0.004, respectively). In addition, high Ki-67 expression was significantly associated with poor prognosis (p = 0.002), which was further confirmed using a multivariate Cox regression hazards model (Hazard Ratio (HR) = 1.797, 95% confidence interval (CI) = 1.038–3.111, p = 0.026). In conclusion, Ki-67 expression may be a significant prognostic factor in epithelial ovarian cancer.

Ki-67; Ovarian cancer; Survival; Prognosis

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Wichmann IA, Cuello MA. Obesity and gynecological cancers: a toxic relationship. International Journal of Gynecology & Obstetrics. 2021; 155: 123–134.

[3] Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian cancer-insights into platinum resistance and overcoming it. Medicina. 2023; 59: 544.

[4] Ciucci A, Buttarelli M, Fagotti A, Scambia G, Gallo D. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. Cellular and Molecular Life Sciences. 2022; 79: 364.

[5] McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, et al. Fifth ovarian cancer consensus conference: individualized therapy and patient factors. Annals of Oncology. 2017; 28: 702–710.

[6] El Bairi K, Al Jarroudi O, Afqir S. Inexpensive systemic inflammatory biomarkers in ovarian cancer: an umbrella systematic review of 17 prognostic meta-analyses. Frontiers in Oncology. 2021; 11: 694821.

[7] Pei R, Zhang L, Xie C, Lu Z, Wang G, Yang Z. Prognostic value of Ki-67 expression in patients with extensive-stage small cell lung cancer. Future Oncology. 2017; 13: 1247–1252.

[8] Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clinica Chimica Acta. 2019; 491: 39–45.

[9] Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15: 808.

[10] Sallum LF, Andrade L, Bastos Eloy da Costa L, Ramalho S, Ferracini AC, Natal RA, et al. BRCA1, Ki67, and β-catenin immunoexpression is not related to differentiation, platinum response, or prognosis in women with low-and high-grade serous ovarian carcinoma. International Journal of Gynecological Cancer. 2018; 28: 437–447.

[11] Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and prognostic significance of Ki-67 immunohistochemical expression in surface epithelial ovarian carcinoma. Journal of Clinical and Diagnostic Research. 2017; 11: EC08–EC12.

[12] Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, et al. Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancer: the MITO 37 retrospective study. Cancers. 2023; 15: 1032.

[13] Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15: 808.

[14] Qiu D, Cai W, Zhang Z, Li H, Zhou D. High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis. Archives of Gynecology and Obstetrics. 2019; 299: 1415–1427.

[15] Rödel F, Zhou S, Győrffy B, Raab M, Sanhaji M, Mandal R, et al. The prognostic relevance of the proliferation markers Ki-67 and Plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mRNA and protein expression. Frontiers in Oncology. 2020; 10: 558932.

[16] Grabowski JP, Martinez Vila C, Richter R, Taube E, Plett H, Braicu E, et al. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. International Journal of Gynecologic Cancer. 2020; 30: 498–503.

[17] Hu J, Jiao X, Zhu L, Guo H, Wu Y. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma. BMC Cancer. 2020; 20: 938.

[18] Kaya R, Takanashi H, Nakajima A, Saito R, Yamaguchi N, Morimoto K, et al. Prognostic significance of Ki67 during neoadjuvant chemotherapy in primary unresectable ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2021; 47: 3979–3989.

[19] Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, et al. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network. Human Pathology. 2019; 85: 299–308.

[20] Grabowski JP, Martinez Vila C, Richter R, Taube E, Plett H, Braicu E, et al. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. International Journal of Gynecologic Cancer. 2020; 30: 498–503.